Ultimately, it is hoped that checkpoint inhibitors will improve the overall survival rate for head and neck cancers. “What everyone is most excited about is trying to move these agents rapidly into the clinic for treatment of newly diagnosed head and neck cancer,” Dr. Gillison said. “We’re hopeful that the survival benefit we’re seeing in the recurrent metastatic platinum-refractory setting may translate into more cures in the primary setting.”
Explore this issue:September 2016
Jennifer L.W. Fink is a freelance medical writer based in Wisconsin.